Cobrotoxin could be an effective therapeutic for COVID-19

Acta Pharmacol Sin. 2020 Sep;41(9):1258-1260. doi: 10.1038/s41401-020-00501-7. Epub 2020 Aug 25.

Authors

Fang Lin¹, Paul F Reid², Zheng-Hong Qin³

Affiliations

¹ Laboratory of Aging and Nervous Diseases (SZS0703), Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, China.
² Maitland Pharma, Orlando, Florida, USA.
³ Laboratory of Aging and Nervous Diseases (SZS0703), Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, China. qinzhenhong@suda.edu.cn.

No abstract available

Publication types

Letter

MeSH terms

Betacoronavirus* / drug effects
Betacoronavirus* / metabolism
Blood Coagulation / drug effects
COVID-19
Cobra Neurotoxin Proteins / pharmacology*
Coronavirus Infections* / blood
Coronavirus Infections* / drug therapy
Coronavirus Infections* / immunology
Humans
Immunity, Cellular / drug effects
Inflammation / drug therapy
Neurotoxins / pharmacology
Pandemics*
Pneumonia, Viral* / blood
Pneumonia, Viral* / drug therapy
Pneumonia, Viral* / immunology
Pulmonary Fibrosis / prevention & control
Pulmonary Fibrosis / virology
SARS-CoV-2
Treatment Outcome

Substances

Cobra Neurotoxin Proteins
Neurotoxins